Repligen (NASDAQ:RGEN) Announces Earnings Results

Repligen (NASDAQ:RGEN) posted its quarterly earnings results on Thursday. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03, Zacks reports. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. Repligen updated its FY 2025 guidance to 1.670-1.760 EPS.

Repligen Price Performance

Shares of NASDAQ:RGEN traded up $8.30 during trading on Thursday, reaching $159.03. 629,268 shares of the company’s stock traded hands, compared to its average volume of 567,466. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen has a fifty-two week low of $113.50 and a fifty-two week high of $203.13. The company has a 50-day simple moving average of $155.04 and a 200-day simple moving average of $148.71. The firm has a market cap of $8.91 billion, a PE ratio of -432.41, a P/E/G ratio of 4.08 and a beta of 0.99.

Analysts Set New Price Targets

A number of analysts have commented on the company. Canaccord Genuity Group assumed coverage on Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. TD Cowen initiated coverage on Repligen in a report on Monday, February 10th. They set a “buy” rating and a $200.00 target price for the company. Canaccord Genuity Group assumed coverage on shares of Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. Finally, HC Wainwright cut their price objective on shares of Repligen from $240.00 to $180.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $182.91.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.